STAT+: FDA discloses reasons for rejecting Summit drug

The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:
This is a brief. The reporting belongs to STAT — read the complete story, with full context and credits, at the source.
Read the full story at STAT ↗statnews.com
More from the Health desk
Just in

Strain-specific Ebola vaccines to be trialled in DRC, WHO announces
Just in

Why are measles cases soaring in the US?
Just in

STAT+: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and more

What redesigning medical school might look like
